Vitamin D Receptor Genetic Polymorphisms and Prostate Cancer Risk: A Meta-analysis of 36 Published Studies

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2009 Aug 18

PMID 19684888

Citations 21

Authors

Ming Yin

Sheng Wei

Qingyi Wei

Affiliations

Soon will be listed here.

Abstract

To update data on the role of vitamin D receptor (VDR) single nucleotide polymorphisms (SNPs) in susceptibility to prostate cancer, we performed a meta-analysis of 36 eligible publications on the association of Taql, Apal, Bsml, Fokl and CDX2 SNPs of the VDR gene with prostate cancer risk. Our study suggested that the Taql t and Bsml B alleles were associated with reduced prostate cancer risk among all study populations. Stratified analysis by ethnicity revealed that the Apal a allele was associated with reduced prostate cancer risk only among Asian populations, whereas the Fokl f allele showed a trend of increased prostate cancer risk only among Caucasian populations in a dominant model, independent of tumor stage (local or advanced). These results suggest that VDR polymorphisms may be potential biomarkers for prostate cancer susceptibility.

Citing Articles

polymorphism and prostate cancer prognosis.

El-Attar A, Hussein S, Salama M, Ibrahim H, AlKaramany A, Elsawi M Curr Urol. 2023; 16(4):246-255.

PMID: 36714231 PMC: 9875206. DOI: 10.1097/CU9.0000000000000141.

Lack of association between the risk of prostate cancer and vitamin D receptor polymorphism: a meta-analysis of 27 published studies.

Kang S, Zhao Y, Wang L, Liu J, Chen X, Liu X Cancer Manag Res. 2018; 10:2377-2387.

PMID: 30122987 PMC: 6078094. DOI: 10.2147/CMAR.S171305.

Admixture Mapping Links RACGAP1 Regulation to Prostate Cancer in African Americans.

Wilson B, Ricks-Santi L, Mason T, Abbas M, Kittles R, Dunston G Cancer Genomics Proteomics. 2018; 15(3):185-191.

PMID: 29695400 PMC: 5971010. DOI: 10.21873/cgp.20076.

Vitamin D receptor I polymorphism and the risk of prostate cancer: a meta-analysis.

Kang S, Zhao Y, Wang L, Liu J, Chen X, Liu X Oncotarget. 2018; 9(6):7136-7147.

PMID: 29467956 PMC: 5805542. DOI: 10.18632/oncotarget.23606.

Study of Vitamin D Receptor Gene Polymorphism (FokI, TaqI and ApaI) Among Prostate Cancer Patients in North India.

Kambale P, Haldar D, Kabi B, Kambale K J Clin Diagn Res. 2017; 11(6):BC05-BC08.

PMID: 28764147 PMC: 5535340. DOI: 10.7860/JCDR/2017/24290.9976.

References

Boyle P, Severi G, Giles G . The epidemiology of prostate cancer. Urol Clin North Am. 2003; 30(2):209-17. DOI: 10.1016/s0094-0143(02)00181-7. View

Bousema J, Bussemakers M, van Houwelingen K, Debruyne F, Verbeek A, de la Rosette J . Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol. 2000; 37(2):234-8. DOI: 10.1159/000020124. View

Chaimuangraj S, Thammachoti R, Ongphiphadhanakul B, Thammavit W . Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls. Asian Pac J Cancer Prev. 2006; 7(1):136-9. View

Onen I, Ekmekci A, Eroglu M, Konac E, Yesil S, Biri H . Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer. Exp Biol Med (Maywood). 2008; 233(12):1608-14. DOI: 10.3181/0803-RM-110. View

Gross C, Eccleshall T, Malloy P, Villa M, Marcus R, Feldman D . The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res. 1996; 11(12):1850-5. DOI: 10.1002/jbmr.5650111204. View

Holick C, Stanford J, Kwon E, Ostrander E, Nejentsev S, Peters U . Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(10):1990-9. DOI: 10.1158/1055-9965.EPI-07-0487. View

Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T . Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int. 2002; 68(4):226-31. DOI: 10.1159/000058440. View

Berndt S, Dodson J, Huang W, Nicodemus K . A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol. 2006; 175(5):1613-23. DOI: 10.1016/S0022-5347(05)00958-4. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

10.

Campbell M, Gombart A, Kwok S, Park S, Koeffler H . The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene. 2000; 19(44):5091-7. DOI: 10.1038/sj.onc.1203888. View

11.

Hayes V, Severi G, Padilla E, Eggleton S, Southey M, Sutherland R . Genetic variants in the vitamin D receptor gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; 14(4):997-9. DOI: 10.1158/1055-9965.EPI-04-0660. View

12.

Luscombe C, French M, Liu S, Saxby M, Jones P, Fryer A . Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes. Carcinogenesis. 2001; 22(9):1343-7. DOI: 10.1093/carcin/22.9.1343. View

13.

Maistro S, Snitcovsky I, Sarkis A, da Silva I, Brentani M . Vitamin D receptor polymorphisms and prostate cancer risk in Brazilian men. Int J Biol Markers. 2004; 19(3):245-9. DOI: 10.1177/172460080401900311. View

14.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

15.

Lau J, Ioannidis J, Schmid C . Quantitative synthesis in systematic reviews. Ann Intern Med. 1998; 127(9):820-6. DOI: 10.7326/0003-4819-127-9-199711010-00008. View

16.

Li H, Stampfer M, Hollis J, Mucci L, Gaziano J, Hunter D . A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007; 4(3):e103. PMC: 1831738. DOI: 10.1371/journal.pmed.0040103. View

17.

Corder E, Guess H, Hulka B, Friedman G, Sadler M, Vollmer R . Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993; 2(5):467-72. View

18.

Valrance M, Welsh J . Breast cancer cell regulation by high-dose Vitamin D compounds in the absence of nuclear vitamin D receptor. J Steroid Biochem Mol Biol. 2004; 89-90(1-5):221-5. DOI: 10.1016/j.jsbmb.2004.03.082. View

19.

Whitfield G, Remus L, Jurutka P, Zitzer H, Oza A, Dang H . Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001; 177(1-2):145-59. DOI: 10.1016/s0303-7207(01)00406-3. View

20.

Huang S, Chou Y, Chang W, Wu M, Chen Y, Yu C . Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett. 2004; 207(1):69-77. DOI: 10.1016/j.canlet.2003.12.006. View